DOCSLIB.ORG

Role of Thyrotrophin Releasing Hormone and Corticotrophin Releasing Factor in Stress Related Alterations of Gastrointestinal Motor Function C Beglinger, L Degen

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Role of Thyrotrophin Releasing Hormone and Corticotrophin Releasing Factor in Stress Related Alterations of Gastrointestinal Motor Function C Beglinger, L Degen i45 VISCERAL PERCEPTION Gut: first published as 10.1136/gut.51.suppl_1.i45 on 1 July 2002. Downloaded from Role of thyrotrophin releasing hormone and corticotrophin releasing factor in stress related alterations of gastrointestinal motor function C Beglinger, L Degen ............................................................................................................................. Gut 2002;51(Suppl I):i45–i49 There is a growing body of experimental and clinical ades ago, pioneer neuropharmacological studies evidence to indicate that stress influences identified the brain as a prime site of action for peptides that alter gastrointestinal function.1–4 gastrointestinal motility. The most common pattern of Over a dozen peptides which modify gastro- gastrointestinal motor alterations induced by a variety of intestinal motor activity and alter transit in rats, different stress factors is that of delayed gastric cats, rabbits, and dogs have been shown to act within the brain.4–7 However, the physiological emptying and accelerated colonic transit. Central role of these peptides is still unclear. The reasons administration of corticotrophin releasing factor mimics for this lack of understanding are threefold. both of these effects. This review focuses on the effects Firstly, specific receptor antagonists are not available for most of these peptides which means of two centrally acting peptides known to influence that it is difficult to examine the endogenous gastrointestinal motility and transit in experimental release of these substances from the CNS in animals: thyrotrophin releasing hormone and response to physical events. Secondly, it is often necessary to undertake experimental studies on corticotrophin releasing factor. The biological actions of surgical preparations or by insertion of needles these peptides are discussed in relation to the motility into brain structures. Although such studies pro- changes and pathways involved in their actions. vide valuable information about the pathways that modulate gastrointestinal functions, their .......................................................................... conclusions cannot be interpreted in terms of normal physiology. The third complication arises SUMMARY from the fact that many of the regulatory circuits http://gut.bmj.com/ Thyrotrophin releasing hormone (TRH) is re- operate under the control of more than one leased from nerve terminals which influence the mechanism. Studies in unconscious animals can activity of vagal neurones projecting to the stom- provide useful data about specific pathways but ach and gastrointestinal tract, and is thought to compensatory processes are involved in intact act as a mediator of vagally stimulated gastro- animals to ensure that the overall physiology intestinal motility during cold or other stressful remains unchanged. stimuli. Corticotrophin releasing factor (CRF) This review focuses on the effects of two on September 30, 2021 by guest. Protected copyright. plays an important role in the regulation of centrally acting peptides known to influence behavioural and autonomic responses to stress, gastrointestinal motility and transit in experi- 14 489 and it has been proposed that hypersecretion of mental animals: TRH and CRF. The biological CRF in the brain may contribute to the patho- actions of these peptides will be discussed in rela- physiology of stress related exacerbation of irrita- tion to the motility changes and pathways ble bowel syndrome (IBS). Centrally adminis- involved in their actions. For example, a growing tered CRF inhibits gastric emptying while body of evidence suggests that TRH and CRF both stimulating colonic motor function. In rats, these play a role in mediating stress induced alterations in gastrointestinal motor function.67 Wherever effects are mediated by CRF2 receptors which modulate vagal and sacral parasympathetic out- possible, the review will also address how these flow. CRF also activates colonic transit and faecal findings relate to normal physiology. excretion elicited by stress. This response involves CRF1 receptors. CRF may also act peripherally, STRUCTURE AND BIOCHEMISTRY OF TRH especially in patients with inflammatory or post- AND CRF infectious conditions. TRH (pGlu-His-Pro-NH2) was the first hypothal- amic releasing peptide to be discovered. Based on See end of article for its actions (regulation of thyrotrophin or thyroid authors’ affiliations INTRODUCTION ....................... During the last three decades, a large number of Correspondence to: brain peptides have been characterised using the ................................................. Professor C Beglinger, techniques of biochemistry, immunohistochemis- Division of try, molecular biology, and physiology. Identifica- Abbreviations: ACTH, adrenocorticotrophic hormone; Gastroenterology, tion of these peptides has led to an explosion in CNS, central nervous system; CRF, corticotrophin releasing factor; IBS, irritable bowel syndrome; LPS, lipopoly University Hospital, 4031 our understanding of their biological action and Basel, Switzerland; -saccharide; alpha-MSH, melanocyte stimulating hormone; [email protected] function in the central nervous system (CNS), PVN, paraventricular nucleus; TRH, thyrotrophin releasing ....................... spinal cord, and enteric nervous system. Two dec- hormone; 5-HT, serotonin. www.gutjnl.com i46 Beglinger, Degen stimulating hormone secretion) it was primarily considered to suggest that TRH is released from nerve terminals which be a physiological regulator of pituitary function.10 11 Further influence the activity of vagal neurones projecting into the 429 studies unexpectedly identified TRH in other brain areas, and stomach and the gastrointestinal tract. Gut: first published as 10.1136/gut.51.suppl_1.i45 on 1 July 2002. Downloaded from based on these findings additional experiments were per- Environmental stress such as exposure to cold are known to formed which showed that this peptide exerts behavioural stimulate brain TRH.32–34 Exposure to cold induces similar effects which are independent of its effects on the pituitary- effects on gastric and gastrointestinal motility as those thyroid axis.1 observed following central injection of TRH.4 Perhaps, more CRF is a 41 amino acid peptide that was characterised two importantly, cold exposure has also been shown to be associ- decades ago.12 The peptide plays a regulatory role in the control ated with accelerated gastric emptying and diarrhoea in of pituitary adrenocorticotrophic hormone (ACTH) secretion rats.32 34 These results imply that medullary TRH may act as a and, in common with TRH, it exerts behavioural, endocrine, mediator of vagally stimulated gastrointestinal motility and motility responses to stress by actions that are independ- during cold or other stressful stimuli. ent of those at the pituitary-ACTH axis.12 13 These findings form the basis for ongoing investigations of the role of endog- EFFECT OF CRF ON GASTROINTESTINAL MOTILITY enous CRF in the brain in terms of modifying gastrointestinal A variety of reports have established that CRF injected into the function and a putative role in stress induced changes in cerebrospinal fluid acts in the brain to inhibit gastric and/or gastrointestinal motor activity.4–6 gastrointestinal motility.35 36 Its actions are mediated by an The actions of CRF have been shown to be mediated through interaction with specific high affinity seven transmembrane activation of specific receptors.14 To date, two CRF receptors, bound receptors that are coupled to a guanine nucleotide 14 37 designated CRF1 and CRF2, have been identified through stimulatory factor signalling protein. To date, two distinct 14 molecular cloning from distinct genes in rats and in humans. CRF receptor subtypes, CRF1 and CRF2, have been cloned and 614 Advances have also been made in the development of potent characterised from rat and human brains. The CRF1 receptor CRF receptor antagonists. These are very helpful tools for is the predominant form localised in the pituitary, olfactory further investigating the physiological importance of CRF. One bulb, and cerebral cortex. The CRF2 receptor is primarily such agent, astressin (cyclo-(30–33)-[D-Phe12, Nle21,38, located in the lateral septum, hypothalamus, amygdala, and 6 Glu30, Lys33] CRF12–41) is a derivative of CRF which has a low brain stem. CRF2 receptors exist in multiple forms (alpha and intrinsic activity and a high affinity for both CRF1 and CRF2 beta) as splice variants differing in their extracellular amino 15 14 receptors. Astressin has been shown to block the effects of acid NH2 terminal domains and in their distribution. 16–18 exogenous CRF on gastric and colonic motor activity and to CRF2 receptor alpha is located on brain neurones, and CRF2 prevent stress related alterations of gastrointestinal motor receptor beta is found in non-neural brain tissue and in the function.717 Other non-peptide antagonists have been devel- periphery (for example, gastrointestinal tract).38 Several stud- 19 oped which display selectivity for CRF1 or CRF2 receptors. ies have established that CRF decreases gastric emptying after injection of the peptide into the cerebrospinal fluid; CRF2 EFFECTS OF CENTRAL TRH ON GASTROINTESTINAL receptors are thought to mediate this action.19 38 In human MOTILITY brain, unlike rat brain, another CRF2 receptor splice variant 38 Intracerebroventricular injection of TRH induces a rapid and has been identified: the CRF2 receptor gamma. long lasting contractile response in the stomach,
Load more

Recommended publications
  • The Impact of the Nonpeptide Corticotropin-Releasing Hormone Antagonist Antalarmin on Behavioral and Endocrine Responses to Stress*
    0013-7227/99/$03.00/0 Vol. 140, No. 1 Endocrinology Printed in U.S.A. Copyright © 1999 by The Endocrine Society The Impact of the Nonpeptide Corticotropin-Releasing Hormone Antagonist Antalarmin on Behavioral and Endocrine Responses to Stress* TERRENCE DEAK, KIEN T. NGUYEN, ANDREA L. EHRLICH, LINDA R. WATKINS, ROBERT L. SPENCER, STEVEN F. MAIER, JULIO LICINIO, MA-LI WONG, GEORGE P. CHROUSOS, ELIZABETH WEBSTER, AND PHILIP W. GOLD Department of Psychology (T.D., K.T.N., A.L.E., L.R.W., R.L.S., S.F.M.), University of Colorado, Boulder, Colorado 80309-0345; Clinical Neuroendocrinology Branch (J.L., M.-L.W., P.W.G.), National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892-1284; and Developmental Neuroendocrinology Branch (G.P.C., E.W.), National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-1284 ABSTRACT Furthermore, because rats previously exposed to inescapable shock The nonpeptide CRH antagonist antalarmin has been shown to (IS; 100 shocks, 1.6 mA, 5 sec each), demonstrate enhanced fear block both behavioral and endocrine responses to CRH. However, it’s conditioning, we investigated whether this effect would be blocked by potential activity in blunting behavioral and endocrine sequelae of antalarmin. Antalarmin (20 mg/kgz2 ml ip) impaired both the induc- stressor exposure has not been assessed. Because antagonism of cen- tion and expression of conditioned fear. In addition, antalarmin tral CRH by a-helical CRH attenuates conditioned fear responses, we blocked the enhancement of fear conditioning produced by prior ex- sought to test antalarmin in this regard.
    [Show full text]
  • Adverse Effects of Stress on Drug Addiction
    Making a bad thing worse: adverse effects of stress on drug addiction Jessica N. Cleck, Julie A. Blendy J Clin Invest. 2008;118(2):454-461. https://doi.org/10.1172/JCI33946. Review Series Sustained exposure to various psychological stressors can exacerbate neuropsychiatric disorders, including drug addiction. Addiction is a chronic brain disease in which individuals cannot control their need for drugs, despite negative health and social consequences. The brains of addicted individuals are altered and respond very differently to stress than those of individuals who are not addicted. In this Review, we highlight some of the common effects of stress and drugs of abuse throughout the addiction cycle. We also discuss both animal and human studies that suggest treating the stress- related aspects of drug addiction is likely to be an important contributing factor to a long-lasting recovery from this disorder. Find the latest version: https://jci.me/33946/pdf Review series Making a bad thing worse: adverse effects of stress on drug addiction Jessica N. Cleck and Julie A. Blendy Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. Sustained exposure to various psychological stressors can exacerbate neuropsychiatric disorders, including drug addiction. Addiction is a chronic brain disease in which individuals cannot control their need for drugs, despite negative health and social consequences. The brains of addicted individuals are altered and respond very differently to stress than those of individuals who are not addicted. In this Review, we highlight some of the common effects of stress and drugs of abuse throughout the addiction cycle.
    [Show full text]
  • Expression and Localization of Gastrin Messenger RNA and Peptide in Spermatogenic Cells
    Expression and localization of gastrin messenger RNA and peptide in spermatogenic cells. M Schalling, … , T Hökfelt, J F Rehfeld J Clin Invest. 1990;86(2):660-669. https://doi.org/10.1172/JCI114758. Research Article In previous studies we have shown that the gene encoding cholecystokinin (CCK) is expressed in spermatogenic cells of several mammalian species. In the present study we show that a gene homologous to the CCK-related hormone, gastrin, is expressed in the human testis. The mRNA hybridizing to a human gastrin cDNA probe in the human testis was of the same size (0.7 kb) as gastrin mRNA in the human antrum. By in situ hybridization the gastrinlike mRNA was localized to seminiferous tubules. Immunocytochemical staining of human testis revealed gastrinlike peptides in the seminiferous tubules primarily at a position corresponding to spermatids and spermatozoa. In ejaculated spermatozoa gastrinlike immunoreactivity was localized to the acrosome. Acrosomal localization could also be shown in spermatids with electron microscopy. Extracts of the human testis contained significant amounts of progastrin, but no bioactive amidated gastrins. In contrast, ejaculated sperm contained mature carboxyamidated gastrin 34 and gastrin 17. The concentration of gastrin in ejaculated human spermatozoa varied considerably between individuals. We suggest that amidated gastrin (in humans) and CCK (in other mammals) are released during the acrosome reaction and that they may be important for fertilization. Find the latest version: https://jci.me/114758/pdf Expression and Localization of Gastrin Messenger RNA and Peptide in Spermatogenic Cells Martin Schalling,* Hhkan Persson,t Markku Pelto-Huikko,*9 Lars Odum,1I Peter Ekman,I Christer Gottlieb,** Tomas Hokfelt,* and Jens F.
    [Show full text]
  • WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V.
    [Show full text]
  • Neuropeptides: Implications for Alcoholism
    Journal of Neurochemistry, 2004, 89, 273–285 doi:10.1111/j.1471-4159.2004.02394.x REVIEW Neuropeptides: implications for alcoholism Michael S. Cowen*, , Feng Chen*, and Andrew J. Lawrence*, *The Howard Florey Institute, University of Melbourne, VIC 3010, Australia Department of Pharmacology, Monash University, VIC 3800 Australia Abstract (CRF), urocortin I and neuropeptide Y (NPY) in deleterious The role of neuromodulatory peptides in the aetiology of and excessive alcohol consumption, focussing on specific alcoholism has been relatively under-explored; however, the brain regions, in particular the central nucleus of the development of selective ligands for neuropeptide receptors, amygdala, that appear to be implicated in the pathophysi- the characterization and cloning of receptors, and the ology of alcoholism. The review also outlines potential development of transgenic mouse models have greatly directions for further research to clarify neuropeptide facilitated this analysis. The present review considers the involvement in neuromodulation within discrete brain nuclei most recent preclinical evidence obtained from animal pertinent to behavioural patterns. models for the role of two of the opioid peptides, namely J. Neurochem. (2004) 89, 273–285. b-endorphin and enkephalin; corticotropin-releasing factor Alcohol causes as much, if not more death and disabilityas analysis. However, drugs that interact with neuropeptide measles, malaria, tobacco or illegal drugs (World Health systems have great potential in the pharmacotherapy of Organization, 2001) . In economic terms, alcohol abuse has alcoholism: witness the widespread (although somewhat less been estimated at US$167 billion per year; however, ‘in than satisfactory) use of the opioid antagonist naltrexone in human terms, the costs are incalculable’ (National Institute the treatment of alcoholism (O’Malley et al.
    [Show full text]
  • Low Ambient Temperature Lowers Cholecystokinin and Leptin Plasma Concentrations in Adult Men Monika Pizon, Przemyslaw J
    The Open Nutrition Journal, 2009, 3, 5-7 5 Open Access Low Ambient Temperature Lowers Cholecystokinin and Leptin Plasma Concentrations in Adult Men Monika Pizon, Przemyslaw J. Tomasik*, Krystyna Sztefko and Zdzislaw Szafran Department of Clinical Biochemistry, University Children`s Hospital, Krakow, Poland Abstract: Background: It is known that the low ambient temperature causes a considerable increase of appetite. The mechanisms underlying the changes of the amounts of the ingested food in relation to the environmental temperature has not been elucidated. The aim of this study was to investigate the effect of the short exposure to low ambient temperature on the plasma concentration of leptin and cholecystokinin. Methods: Sixteen healthy men, mean age 24.6 ± 3.5 years, BMI 22.3 ± 2.3 kg/m2, participated in the study. The concen- trations of plasma CCK and leptin were determined twice – before and after the 30 min. exposure to + 4 °C by using RIA kits. Results: The mean value of CCK concentration before the exposure to low ambient temperature was 1.1 pmol/l, and after the exposure 0.6 pmol/l (p<0.0005 in the paired t-test). The mean values of leptin before exposure (4.7 ± 1.54 μg/l) were also significantly lower than after the exposure (6.4 ± 1.7 μg/l; p<0.0005 in the paired t-test). However no significant cor- relation was found between CCK and leptin concentrations, both before and after exposure to low temperature. Conclusions: It has been known that a fall in the concentration of CCK elicits hunger and causes an increase in feeding activity.
    [Show full text]
  • Potential PET Ligands for Imaging of Cerebral VPAC and PAC Receptors: Are NonPeptide Small Molecules Superior to Peptide Compounds?
    World Journal of Neuroscience, 2015, 5, 364384 Published Online November 2015 in SciRes. http://www.scirp.org/journal/wjns http://dx.doi.org/10.4236/wjns.2015.55036 Potential PET Ligands for Imaging of Cerebral VPAC and PAC Receptors: Are NonPeptide Small Molecules Superior to Peptide Compounds? Margit Pissarek INM5, Nuclear Chemistry, Institute of Neurosciences and Medicine, Research Centre Jülich, Jülich, Germany Received 15 August 2015; accepted 13 November 2015; published 17 November 2015 Copyright © 2015 by author and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/ Abstract Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) have been known for decades to mediate neuroendocrine and vasodilative actions via Gprotein coupled receptors of Class B. These are targets of imaging probes for positron emission tomogra phy (PET) or single photon emission tomography (SPECT) in tumor diagnostics and tumor grading. However, they play only a subordinate role in the development of tracers for brain imaging. Diffi culties in development of nonpeptide ligands typical for cerebral receptors of PACAP and VIP are shared by all members of Class B receptor family. Essential landmarks have been confirmed for understanding of structural details of Class B receptor molecular signalling during the last five years. High relevance in the explanation of problems in ligand development for these receptors is admitted to the large Nterminal ectodomain markedly different from Class A receptor binding sites and poorly suitable as orthosteric binding sites for the most smallmolecule compounds. The present study is focused on the recently available receptor ligands for PAC1, VPAC1 and VPAC2 receptors as well as potential smallmolecule lead structures suitable for use in PET or SPECT.
    [Show full text]
  • Role of Dorsal Medial Prefrontal Cortex Dopamine D1-Family Receptors in Relapse to High-Fat Food Seeking Induced by the Anxiogenic Drug Yohimbine
    Neuropsychopharmacology (2011) 36, 497–510 & 2011 American College of Neuropsychopharmacology. All rights reserved 0893-133X/11 $32.00 www.neuropsychopharmacology.org Role of Dorsal Medial Prefrontal Cortex Dopamine D1-Family Receptors in Relapse to High-Fat Food Seeking Induced by the Anxiogenic Drug Yohimbine 1 1 1 1 1 Sunila G Nair , Brittany M Navarre , Carlo Cifani , Charles L Pickens , Jennifer M Bossert and Yavin Shaham*,1 1 Behavioral Neuroscience Branch, NIDA/IRP/NIH/DHHS, Baltimore, MD, USA In humans, relapse to maladaptive eating habits during dieting is often provoked by stress. In rats, the anxiogenic drug yohimbine, which causes stress-like responses in both humans and nonhumans, reinstates food seeking in a relapse model. In this study, we examined the role of medial prefrontal cortex (mPFC) dopamine D1-family receptors, previously implicated in stress-induced reinstatement of drug seeking, in yohimbine-induced reinstatement of food seeking. We trained food-restricted rats to lever press for 35% high-fat pellets every other day (9–15 sessions, 3 h each); pellet delivery was accompanied by a discrete tone-light cue. We then extinguished operant responding for 10–16 days by removing the pellets. Subsequently, we examined the effect of yohimbine (2 mg/kg, i.p.) on reinstatement of food seeking and Fos (a neuronal activity marker) induction in mPFC. We then examined the effect of systemic injections of the D1-family receptor antagonist SCH23390 (10 mg/kg, s.c.) on yohimbine-induced reinstatement and Fos induction, and that of mPFC SCH23390 (0.5 and 1.0 mg/side) injections on this reinstatement.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • G Protein‐Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
    [Show full text]
  • WO 2015/072853 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072853 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 45/06 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61K 31/5517 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61P 31/22 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 31/551 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/NL20 14/050781 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 13 November 2014 (13.1 1.2014) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 61/903,433 13 November 2013 (13.
    [Show full text]
  • A Cholecystokinin-Mediated Pathway to the Paraventricular Thalamus Is Recruited in Chronically Stressed Rats and Regulates Hypothalamic-Pituitary-Adrenal Function
    The Journal of Neuroscience, July 15, 2000, 20(14):5564–5573 A Cholecystokinin-Mediated Pathway to the Paraventricular Thalamus Is Recruited in Chronically Stressed Rats and Regulates Hypothalamic-Pituitary-Adrenal Function Seema Bhatnagar,2 Victor Viau,1 Alan Chu,1 Liza Soriano,1 Onno C. Meijer,1 and Mary F. Dallman1 1Department of Physiology, University of California at San Francisco, San Francisco, California 94143-0444, and 2Department of Psychology, University of Michigan, Ann Arbor, Michigan 48109 Chronic stress alters hypothalamic-pituitary-adrenal (HPA) re- ceptor antagonist PD 135,158 into the PVTh before restraint in sponses to acute, novel stress. After acute restraint, the posterior control and chronically cold-stressed rats. ACTH responses to division of the paraventricular thalamic nucleus (pPVTh) exhibits restraint stress were augmented by PD 135,158 only in chroni- increased numbers of Fos-expressing neurons in chronically cally stressed rats but not in controls. In addition, CCK-B recep- cold-stressed rats compared with stress-naı¨vecontrols. Further- tor mRNA expression in the pPVTh was not altered by chronic more, lesions of the PVTh augment HPA activity in response to cold stress. We conclude that previous chronic stress specifically novel restraint only in previously stressed rats, suggesting that facilitates the release of CCK into the pPVTh in response to the PVTh is inhibitory to HPA activity but that inhibition occurs acute, novel stress. The CCK is probably secreted from neurons only in chronically stressed rats. In this study, we further exam- in the lateral parabrachial, the periaqueductal gray, and/or the ined pPVTh functions in chronically stressed rats.
    [Show full text]